[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355747-105":59,"doc-detail-355747-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","idh1-and-idh2-mutated-myeloid-neoplasms-mutational-pattern-clonal-hierarchy-and-the-role-in-aml-transformation","IDH1-and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation","","Genetic alterations in isocitrate dehydrogenase (IDH) genes, IDH1 and IDH2, occur recurrently in myeloid neoplasms and are clinically targeted by small-molecule inhibitors. Using a large cohort of 12,071 patients, the study quantifies IDH mutation frequencies across AML, MDS, and CMML, characterizes differences by age, disease entity, and mutation hot spots, and infers clonal hierarchy. High IDH1 prevalence in secondary AML is used to support acquisition during AML transition and informs sequential molecular testing and targeted treatment decisions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/idh1-and-idh2-mutated-myeloid-neoplasms-mutational-pattern-clonal-hierarchy-and-the-role-in-aml-transformation/355747/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/idh1-and-idh2-mutated-myeloid-neoplasms-mutational-pattern-clonal-hierarchy-and-the-role-in-aml-transformation/355747.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How common are IDH1 and IDH2 mutations across AML, MDS, and CMML?","Question",{"text":113,"@type":114},"IDH mutations were found in 28% of AML patients (IDH1 10%, IDH2 18%), 6.3% of MDS patients (IDH1 1.8%, IDH2 4.6%), and 5.2% of CMML patients (IDH1 0.8%, IDH2 4.4%).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does the study report about clonal hierarchy for IDH mutations?",{"text":118,"@type":114},"The inferred clonal hierarchy suggests IDH mutations are present in the founder clone in many, but not all, patients.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports that IDH1 mutations are acquired during transformation to secondary AML?",{"text":122,"@type":114},"The study reports higher frequencies of IDH1 mutations in secondary AML and myelodysplasia-related AML compared with MDS and CMML, and this acquisition at transition to AML is directly confirmed in a subset analyzed before and after progression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355747,1790560419,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","REGULAR ARTICLE  \nIDH1-and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation  \nSandra Huber, 1,* Flora Goessweiner,1, 2,* Wencke Walter,1 Isolde Summerer,1 Manja Meggendorfer, 1 Rainer Ordemann,1 Christian Pohlkamp, 1 Niclas Kneisel,3 Claudia Haferlach, 1 Wolfgang Kern, 1 Torsten Haferlach, 1 Sabit Delic, 1 and Gregor Hoermann 1 1 MLL Munich Leukemia Laboratory, Munich, Germany; 2 Ludwig Maximilian University, Munich, Germany; and 3Servier Germany, Munich, Germany  \nKey Points  \n• The comutational pattern of IDH mutations differs by age, between entities, and between mutation hot spots.  \n• IDH1 mutations are frequently acquired at transformation to secondary AML.  \nMutations in the isocitrate dehydrogenase (IDH) genes, IDH1 and IDH2, are recurrently found in patients with myeloid neoplasms (MN) and clinically targeted by small-molecule inhibitors. We aimed to comprehensively study the genetic pattern and underlying clonal architecture in a large cohort of 12 071 patients (acute myeloid leukemia [AML], n = 4113; myelodysplastic neoplasms [MDS], n = 6316; or chronic myelomonocytic leukemia [CMML], n = 1642). IDH mutations were found in 28% of patients with AML (IDH1, 10%; IDH2, 18%), 6.3% of patients with MDS (IDH1, 1.8%; IDH2, 4.6%), and 5.2% of patients with CMML (IDH1, 0.8%; IDH2, 4.4%) . IDH mutations were enriched in subgroups with increased blasts but almost absent within MDS with biallelic TP53 inactivation. The comutational pattern differed by age, between MN, and between mutation hot spots. The underlying clonal hierarchy suggested that IDH mutations were present in the founder clone in many, but not all, patients. Finally, the high frequencies of IDH1 mutations in secondary AML and myelodysplasia-related AML (both 9.5%), compared with MDS (1.8%) and CMML (0.8%), indicate a frequent acquisition of this mutation at the transition to AML, which was directly confirmed in a subset of patients analyzed before and after progression. Overall, our findings have potential implications for sequential molecular testing and targeted treatment decisions.  \nIntroduction  \nIsocitrate dehydrogenase 1 (IDH1) and IDH2 physiologically catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate.1 As such, IDH is involved in metabolic processes. First, by providing α-ketoglutarate, which acts as a cofactor for several enzymes and is a substrate of the citric acid cycle. Second, it drives ATP production, glutathione reduction, and cholesterol synthesis by producing reduced NAD phosphate.1 Somatic mutations, in particular in codons IDH1 p.Arg132, IDH2 p.Arg172, and IDH2 p.Arg140 located at the active site of the enzyme, are recurrently found in myeloid neoplasms (MN) altering the enzymatic activity of IDH.2,3 The mutations disrupt the normal enzymatic function while driving the conversion from α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG) .4 2-HG again inhibits α-ketoglutarate–dependent dioxygenase-type enzymes such as TET2 leading to hypermethylation and disrupted cell differentiation.5,6 Small-molecule inhibitors have been developed to target mutated IDH enzymes selectively.7 The orally available mutant IDH1 inhibitor  \nSubmitted 12 December 2025; accepted 2 March 2026; prepublished online on Blood Advances First Edition 20 March 2026. [https://doi.org/10.1182/](https://doi.org/10.1182/)[ ](https://doi.org/10.1182/)[bloodadvances.2025019387](bloodadvances.2025019387.)[.](bloodadvances.2025019387.)  \n*S.H. and F.G. contributed equally to this study.  \nThe data sets generated during and/or analyzed during this study are available from the corresponding author, Gregor Hoermann ([gregor.hoermann@mll.com](gregor.hoermann@mll.com)), upon reasonable request.  \nThe full-text version of this article contains a data supplement.  \n© 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives ","cbCaiju7da926UzN","https://ap.wps.com/l/cbCaiju7da926UzN","pdf",1402795,"English","# Key Points\n# Introduction\n# Methods\n## Patient cohort and samples","[{\"question\":\"How common are IDH1 and IDH2 mutations across AML, MDS, and CMML?\",\"answer\":\"IDH mutations were found in 28% of AML patients (IDH1 10%, IDH2 18%), 6.3% of MDS patients (IDH1 1.8%, IDH2 4.6%), and 5.2% of CMML patients (IDH1 0.8%, IDH2 4.4%).\"},{\"question\":\"What does the study report about clonal hierarchy for IDH mutations?\",\"answer\":\"The inferred clonal hierarchy suggests IDH mutations are present in the founder clone in many, but not all, patients.\"},{\"question\":\"What evidence supports that IDH1 mutations are acquired during transformation to secondary AML?\",\"answer\":\"The study reports higher frequencies of IDH1 mutations in secondary AML and myelodysplasia-related AML compared with MDS and CMML, and this acquisition at transition to AML is directly confirmed in a subset analyzed before and after progression.\"}]","IDH1-and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation | PDF",1790120774,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24b815e1716ce64afd3b60855a76dca2.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b392dbca79fd0ad197ac9edb8e13f84.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8abd20161034b5567391643623de3eb5.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebaa057154669950cb727fa9bbc64a5f.webp",980,1292]